-
Something wrong with this record ?
Chemosensitization of tumors via simultaneous delivery of STAT3 inhibitor and doxorubicin through HPMA copolymer-based nanotherapeutics with pH-sensitive activation
M. Kovář, V. Šubr, K. Běhalová, M. Studenovský, D. Starenko, J. Kovářová, P. Procházková, T. Etrych, L. Kostka
Language English Country United States
Document type Journal Article
- MeSH
- Doxorubicin * pharmacology therapeutic use MeSH
- Hydrogen-Ion Concentration MeSH
- Polymethacrylic Acids MeSH
- Humans MeSH
- Methacrylates * MeSH
- Mice MeSH
- Neoplasms * drug therapy MeSH
- STAT3 Transcription Factor metabolism MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Mice MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
We synthesized three novel STAT3 inhibitors (S3iD1-S3iD3) possessing oxoheptanoic residue enabling linkage to HPMA copolymer carrier via a pH-sensitive hydrazone bond. HPMA copolymer conjugates bearing doxorubicin (Dox) and our STAT3 inhibitors were synthesized to evaluate the anticancer effect of Dox and STAT3 inhibitor co-delivery into tumors. S3iD1-3 and their copolymer-bound counterparts (P-S3iD1-P-S3iD3) showed considerable in vitro cytostatic activities in five mouse and human cancer cell lines with IC50 ~0.6-7.9 μM and 0.7-10.9 μM, respectively. S3iD2 and S3iD3 were confirmed to inhibit the STAT3 signaling pathway. The combination of HPMA copolymer-bound Dox (P-Dox) and P-S3iD3 at the dosage showing negligible toxicity demonstrated significant antitumor activity in B16F10 melanoma-bearing mice and completely cured 2 out of 15 mice. P-Dox alone had a significantly lower therapeutic activity with no completely cured mice. Thus, polymer conjugates bearing STAT3 inhibitors may be used for the chemosensitization of chemorefractory tumors.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24007320
- 003
- CZ-PrNML
- 005
- 20240909133012.0
- 007
- ta
- 008
- 240412e20231227xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.nano.2023.102730 $2 doi
- 035 __
- $a (PubMed)38158146
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Kovář, M $u Institute of Microbiology, Czech Academy of Sciences, Vídeňská 1083, 14220 Prague, Czech Republic
- 245 10
- $a Chemosensitization of tumors via simultaneous delivery of STAT3 inhibitor and doxorubicin through HPMA copolymer-based nanotherapeutics with pH-sensitive activation / $c M. Kovář, V. Šubr, K. Běhalová, M. Studenovský, D. Starenko, J. Kovářová, P. Procházková, T. Etrych, L. Kostka
- 520 9_
- $a We synthesized three novel STAT3 inhibitors (S3iD1-S3iD3) possessing oxoheptanoic residue enabling linkage to HPMA copolymer carrier via a pH-sensitive hydrazone bond. HPMA copolymer conjugates bearing doxorubicin (Dox) and our STAT3 inhibitors were synthesized to evaluate the anticancer effect of Dox and STAT3 inhibitor co-delivery into tumors. S3iD1-3 and their copolymer-bound counterparts (P-S3iD1-P-S3iD3) showed considerable in vitro cytostatic activities in five mouse and human cancer cell lines with IC50 ~0.6-7.9 μM and 0.7-10.9 μM, respectively. S3iD2 and S3iD3 were confirmed to inhibit the STAT3 signaling pathway. The combination of HPMA copolymer-bound Dox (P-Dox) and P-S3iD3 at the dosage showing negligible toxicity demonstrated significant antitumor activity in B16F10 melanoma-bearing mice and completely cured 2 out of 15 mice. P-Dox alone had a significantly lower therapeutic activity with no completely cured mice. Thus, polymer conjugates bearing STAT3 inhibitors may be used for the chemosensitization of chemorefractory tumors.
- 650 _2
- $a myši $7 D051379
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a zvířata $7 D000818
- 650 12
- $a doxorubicin $x farmakologie $x terapeutické užití $7 D004317
- 650 12
- $a nádory $x farmakoterapie $7 D009369
- 650 _2
- $a kyseliny polymethakrylové $7 D011109
- 650 _2
- $a koncentrace vodíkových iontů $7 D006863
- 650 _2
- $a transkripční faktor STAT3 $x metabolismus $7 D050796
- 650 12
- $a methakryláty $7 D008689
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Šubr, V $u Institute of Macromolecular Chemistry, Czech Academy of Sciences, Heyrovského nám. 2, 16200 Prague, Czech Republic
- 700 1_
- $a Běhalová, K $u Institute of Microbiology, Czech Academy of Sciences, Vídeňská 1083, 14220 Prague, Czech Republic
- 700 1_
- $a Studenovský, M $u Institute of Macromolecular Chemistry, Czech Academy of Sciences, Heyrovského nám. 2, 16200 Prague, Czech Republic
- 700 1_
- $a Starenko, Daniil $u Institute of Microbiology, Czech Academy of Sciences, Vídeňská 1083, 14220 Prague, Czech Republic $7 xx0322367
- 700 1_
- $a Kovářová, J $u Institute of Microbiology, Czech Academy of Sciences, Vídeňská 1083, 14220 Prague, Czech Republic
- 700 1_
- $a Procházková, P $u Institute of Microbiology, Czech Academy of Sciences, Vídeňská 1083, 14220 Prague, Czech Republic
- 700 1_
- $a Etrych, T $u Institute of Macromolecular Chemistry, Czech Academy of Sciences, Heyrovského nám. 2, 16200 Prague, Czech Republic
- 700 1_
- $a Kostka, L $u Institute of Macromolecular Chemistry, Czech Academy of Sciences, Heyrovského nám. 2, 16200 Prague, Czech Republic. Electronic address: kostka@imc.cas.cz
- 773 0_
- $w MED00167284 $t Nanomedicine $x 1549-9642 $g Roč. 56 (20231227), s. 102730
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38158146 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240412 $b ABA008
- 991 __
- $a 20240909133010 $b ABA008
- 999 __
- $a ok $b bmc $g 2081354 $s 1217087
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 56 $c - $d 102730 $e 20231227 $i 1549-9642 $m Nanomedicine $n Nanomedicine $x MED00167284
- LZP __
- $a Pubmed-20240412
